

18 October 2021

November 2021 Pharmaceutical Schedule Dispatch

Kia ora

This is an early notification of the changes to be announced in the **November 2021** Update to the Pharmaceutical Schedule.

The full Update will be available as a [PDF on our website](#). The changes will be published in the online Schedule around the 23rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

New listings

- Amisulpride (Sulprix) tab 100 mg – Safety medicine, new Pharmacode (p'code 2609401)
- Aqueous cream (GEM Aqueous Cream) crm, 500 g (p'code 2615592)
- Bortezomib (Bortezomib Juno) inj 2.5 mg vial – PCT only – Specialist – Special Authority, section 29 (p'code 2622130)
- Cinacalcet (Cinacalcet Devatis) tab 30 mg (p'code 2615517) and 60 mg (p'code 2615525) – Special Authority-Retail pharmacy and wastage claimable
- Darunavir (Darunavir Mylan) tab 400 mg – Special Authority-Retail pharmacy, bottle pack (p'code 2591286)
- Entacapone (Comtan) tab 200 mg (p'code 2536471)
- Folic acid (Folic Acid multichem) tab 0.8 mg (p'code 2610566)
- Ketoconazole (Sebizole) shampoo 2%, 100 ml OP – maximum of 100 ml per prescription and only on a prescription (p'code 361410)
- Melatonin (Vigisom) tab modified-release 2 mg – Special Authority-Retail pharmacy and no more than 5 tab per day (p'code 2612593)
- Methyldopa (Methyldopa Mylan) tab 250 mg – new Pharmacode (p'code 2500167)
- Prazosin (Apo-Prazosin S29) tab 1 mg (p'code 2625725), 2 mg (p'code 2625733) and 5 mg (p'code 2625741) – section 29 and wastage claimable
- Pyridoxine hydrochloride (Pyridoxine multichem) tab 50 mg – no more than 100 mg per dose and only on a prescription (p'code 2610582)

Changes to restrictions, chemical names and presentations

- Clarithromycin tab 250 mg (Apo-Clarithromycin and Klacid) and grans for oral liq 250 mg per 5 ml (Klacid) – amended restriction criteria
- Infliximab inj 100 mg (Remicade) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
- Oestradiol valerate (Progynova) tab 2 mg – removal of stat dispensing

- Prazosin (Apo-Prazosin and Apo-Prazosin S29) tab 1 mg, 2 mg and 5 mg – removal of subsidy endorsement
- Rituximab (Riximyo) inj 100 mg per 10 ml vial and inj 500 mg per 50 ml vial (Riximyo) and inj 1 mg for ECP (Baxter (Riximyo)) – amended Special Authority criteria
- Secukinumab (Cosentyx) inj 150 mg per ml, 1 ml prefilled syringe – amended Special Authority criteria
- Testosterone undecanoate (Andriol Testocaps) cap 40 mg – addition of subsidy by endorsement

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Beclomethasone dipropionate	Aerosol inhaler, 50 mcg per dose, 200 dose OP Aerosol inhaler, 100 mcg per dose, 200 dose OP	Qvar
Bimatoprost	Eye drop 0.03%, 3 ml OP	Bimatoprost Multichem
Fentanyl	Inj 50 mcg per ml, 2 ml ampoule	Boucher and Muir
Gentamicin sulphate	Inj 10 mg per ml, 1 ml ampoule	DBL Gentamicin
Ibuprofen	Oral liq 20 mg per ml, 200 ml	Ethics
Octreotide	Inj 500 mcg per ml, 1 ml ampoule	Octreotide GH
Phenobarbitone sodium	Inj 200 mcg per ml, 1 ml ampoule	Max Health
Primidone	Tab 250 mg	Apo-Primidone
Zinc and castor oil	Oint, 500 g	Boucher

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Rivastigmine	Patch 9.5 mg per 24 hour	Generic Partners Rivastigmine Patch BNM 10*	

* no subsidy change for this brand for 1 November 2021.